Amgen Scores Partial Victory in Efforts to Maintain OTEZLA Exclusivity
Patently O
APRIL 21, 2023
At the time Amgen’s acquired apremilast, Celgene was involved in Hatch-Waxman litigation with numerous generic challengers, including Sandoz. The district court found the claims of the ‘638 and ‘101 patents to be infringed and not invalid, and enjoined generic apremilast until the expiration of the ‘638 patent in February 2028.
Let's personalize your content